chf interventions to decrease readmissions

recent systematic review/meta-analysis of interventions to prevent readmissions for pts with heart failure (see chf interventions to decrease readmissions annals2014 in dropbox, or Ann Intern Med. 2014;160:774-784). review was funded by Agency for Healthcare Research and Quality (AHRQ)

background:
    --heart failure (chf) is leading cause of hospitalizations (and health care utilization) in US
    --25% of pts admitted with chf are readmitted within 30 days (35% of them readmitted with diagnosis of chf. rest with renal dz, pneumonia, etc)

results:
    --47 trials of diverse interventions to prevent readmission. pts with moderate to severe chf. mean age 70.
    --at 30 days, high intensity home-visiting program (nurse or pharmacist usually) reduced all-cause readmission and combo of that plus death, though low quality of evidence
    --over 3-6 months, home-visiting program and multidisciplinary heart failure clinics reduced all-cause readmission, with high quality of evidence
    --structured telephone support (scheduled calls with structured questions, decision-support-software, etc) reduced chf-specific readmissions but not all-cause readmissions, with moderate quality of evidence
    --home-visiting programs, multidisciplinary heart failure clinics, and structured telephone support reduced mortality
    --BUT, neither telemonitoring (remote physiologic monitoring, eg with EKG, BP, weight, oxygen sats) nor educational programs (in person, or interactive computer-based) reduced readmission or mortality

so, not so surprising, though there is great local, regional, and national variability in post-hospital interventions. the results are certainly consistent with our anecdotal practice, that providing lots of nurse-based home visits (with occasional MD visits) and the availability of nurses to go to the house with minimal notice, decreases ER visits significantly and the seemingly inevitable readmission. seems that interventions with more human interaction (home visits, or even telephone support) do better than high-tech physiologic monitoring (telemonitoring). maybe not so surprising....

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

HDL a negative risk factor? or cholesterol efflux??

Although the data on HDL being protective of atherosclerotic disease is pretty consistent, there are negative studies, and the data on medications which dramatically improve HDL levels (eg, the cholesteryl ester transfer protein --CETP --inhibitors, such as torcetrapib) are clinically disappointing. there have been several explanations for this. for example, some HDL particles are "pro-inflammatory" and elicit an atherosclerotic response (which may be related to apolipoprotein C-III). a new article in NEJM highlights another angle -- that the issue is not the HDL number, but HDL's functionality in the reverse transport of cholesterol, as measured by the cholesterol efflux capacity (see  lipids HDL efflux capacity vs amt NEJM 2014 in dropbox, or  DOI: 10.1056/NEJMoa1409065). This article looks at the Dallas Heart Study, where they measured HDL levels, HDL particle concentrations, and cholesterol efflux capacity in 2924 adults free of cardiovascular disease and followed p
Read more

Drug company shenanigans: narcolepsy drug

I have not done a blog for a long time on drug company shenanigans. So it is my great pleasure to bring up a brand-new drug company approach to garner huge amounts of money (see  https://www.nytimes.com/2023/02/28/business/jazz-narcolepsy-avadel-patents.html?smid=nytcore-ios-share&referringSource=articleShare  ).  Based on an article by  Rebecca Robbins of the New York Times, who has written several articles on drug company excesses   As background, this will be my 42 nd  such blog: for the array, see  https://bucommunitymed.wpengine.com/page/4/?s=drug+company+shenanigans   Th e drug company  approach  this time  to extending  their  patents has a few “interesting” angles: -- this is a medication manufactured by Jazz Pharmaceuticals to treat narcolepsy: there are 2 versions: Xyrem and Xywav (Xywav has less sodium, so is marketed to those who should be on a low sodium diet). These meds are basically derivatives of gammahydroxybutyric acid (GHB)      -- the drug actually has a pretty
Read more

UPDATE: ASCVD risk factor critique

  I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:              -- there is very clear evidence that there are many individual risk factors that are associated with increased risk of a cardiovascu
Read more